At the opening of trading on May 20, the Zhejiang Hisun Pharmaceutical Co.Ltd(600267) share price was closed. As of the closing of the day, it closed at 15.55 yuan / share, up 9.97%.
On the news side, the reason for the sharp rise in share prices comes from an announcement issued by Zhejiang Hisun Pharmaceutical Co.Ltd(600267) on May 19. The announcement pointed out that Zhejiang Hisun Pharmaceutical Co.Ltd(600267) has signed the strategic cooperation agreement and the entrusted production framework agreement with Shanghai Wangshi Biomedical Technology Co., Ltd. The two sides intend to establish strategic cooperation in the fields of product processing, production, international registration and market development of small molecule innovative drug vv116. The agreement is valid for 5 years.
It is noteworthy that Zhejiang Hisun Pharmaceutical Co.Ltd(600267) share price has risen frequently since May 5. Up to now, it has gained 4 limit sectors, with an increase of 48.66%.
clinically proven effective for Omicron
related cooperation remains uncertain
According to the data, vv116 is a nucleoside covid-19 oral drug developed by Shanghai Institute of pharmacy, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, Xinjiang Institute of physical and chemical technology, Chinese Academy of Sciences, Central Asia drug R & D center / China Ukraine medical science and Technology City, Wangshan wangshui and Shanghai Junshi Biosciences Co.Ltd(688180) cooperation, which can inhibit the replication of sars-cov-2. Vv116 has entered phase III of clinical research.
For the production of vv116, Shanghai Junshi Biosciences Co.Ltd(688180) responded to the reporter of Securities Daily: “the company is doing its best to accelerate the development of vv116. At the same time, the company will reasonably arrange the production plan and capacity preparation of products according to the current progress of the project.”
In addition, the reporter also tried to get in touch with Zhejiang Hisun Pharmaceutical Co.Ltd(600267) side, but as of press time, Zhejiang Hisun Pharmaceutical Co.Ltd(600267) side has not replied to this cooperation.
It is noteworthy that on May 19, the day of the announcement of Zhejiang Hisun Pharmaceutical Co.Ltd(600267) s release, the official account of the infection department of Shanghai Huashan Hospital “Huashan infection” announced the clinical research results of vv116 among Chinese Omicron infected people. The data showed that among the patients who used vv116 within 5 days of the first positive nucleic acid test, the average time from the first positive nucleic acid test to negative was 8.56 days, which was less than 11.13 days in the control group.
From the data results, vv116 is effective in the treatment of Omicron.
However, from the statement of the announcement, the cooperation between Zhejiang Hisun Pharmaceutical Co.Ltd(600267) and Shanghai Wangshi biology is still uncertain. The announcement pointed out that at present, the indication of vv116 for the treatment of novel coronavirus pneumonia has not been approved by the State Food and drug administration, and there is uncertainty about whether it has been approved. At the same time, the relevant strategic cooperation methods are not exclusive, and there is uncertainty whether the two sides can finally sign the corresponding contract and the signing time.
domestic covid-19 oral drug
overseas layout is accelerating
For the R & D and production of domestic covid-19 oral drugs, Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd., told reporters that at present, the R & D of domestic covid-19 oral drugs has developed together, and the three drugs have reached the phase III clinical research stage, indicating that the R & D of domestic covid-19 specific drugs is at the international advanced level.
According to the data, the domestic covid-19 oral drugs currently entering the phase 3 clinical research stage include the real biological azvudine, Shanghai Junshi Biosciences Co.Ltd(688180) vv116 and prochloramide, which develops the pharmaceutical industry.
For the above products, Meng Lilian, chief expert of Sichuan Tianfu Health Industry Research Institute, told the reporter of Securities Daily that covid-19 therapeutic drugs are not epidemic prevention drugs after all, and the current market is not in China. However, the R & D and production of relevant drugs have provided more ways for China’s dynamic anti epidemic policy, and also made it possible for China to further unblock its doors and regions.
In the overseas market, both prochloramide and vv116 have performed well. Among them, pukrutamide has obtained EUA or use authorization in Paraguay, Sarajevo state of Bosnia and Herzegovina, the Republic of Ghana, Liberia and other places.
According to public reports, vv116 announced its trade name and pricing in Uzbekistan this month, further from formal commercialization. It is reported that the price of vv116 in Uzbekistan is 185 US dollars per course, equivalent to about 1234 yuan.
For the overseas layout of domestic covid-19 drugs, Deng Zhidong said that at present, there is a huge demand in the international market. At the same time, the product is authorized for emergency use in the overseas market, which will promote and benefit its competition in the Chinese market and form a certain publicity advantage in the market competition.
